HDAC inhibitor sensitization of BRCA-1/2 wild-type high-grade serous ovarian cancer cells to PARPinhibitor treatment (Supplemental Non-Federal Funds)

Project: Research project

Project Details

Description

HDAC inhibitor sensitization of BRCA-1/2 wild-type high-grade serous ovarian cancer cells to PARP inhibitor treatment (Supplemental Non-Federal Funds)
StatusFinished
Effective start/end date9/15/229/30/23

Funding

  • MAYO CLINIC ROCHESTER

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.